Reported 3 days ago
Spectral AI Inc. (NASDAQ:MDAI) is on track to submit its revolutionary DeepView system for FDA approval by mid-2025. The DeepView system, which utilizes multispectral imaging to evaluate burn wound healing, has shown strong performance recently, prompting BTIG to maintain a 'Buy' rating with a price target of $3.00. Positive momentum is also driven by clinical feedback from the UK and Australia, as the company develops a miniaturized version for military applications. Overall, MDAI ranks 10th among trending AI stocks this week, with encouragement from hedge fund interest.
Source: YAHOO